News

Eli Lilly continues to demonstrate remarkable market performance, posting an impressive 32 percent revenue growth over the past twelve months. The pharmaceutical giant's robust financial health is

Die Edwards Lifesciences Corporation, ein führender Anbieter von Herz-Kreislauf-Produkten, wird am 4. März 2025 an der TD Cowen Healthcare Conference teilnehmen. Das Unternehmen mit einer aktuellen

The healthcare insurance giant Unitedhealth experienced a significant market setback on Friday as its stock plummeted more than 7%, deepening the company's recent struggles. The sharp decline came

Die Edwards Lifesciences Aktie präsentiert sich in der aktuellen Marktphase weitgehend stabil, mit einem aktuellen Kurs von 70,33 EUR. Der US-amerikanische Spezialist für

Unitedhealth Group experienced a significant market setback on Friday as its shares plummeted nearly 9% following revelations of a Department of Justice investigation. The probe centers on the

Illumina's stock has plummeted to a 52-week low of $94.72, marking a significant 28% decline from the previous year, despite the biotechnology company's robust annual revenue of $4.37 billion and

The healthcare insurance giant Unitedhealth experienced a dramatic 11% stock decline on Friday following the announcement of a civil fraud investigation by the U.S. Department of Justice (DoJ). The

DaVita's stock has experienced a significant downturn, with shares falling 4% to $148.49, representing a decline of $6.47 per share. This market movement comes in direct response to Berkshire

Der US-Gentechnikspezialist Illumina verzeichnet aktuell eine gemischte Entwicklung an den Börsen. Der Aktienkurs liegt derzeit bei 103,00 USD und konnte einen Tagesgewinn von 1,89 Prozent

Eli Lilly and is strengthening its position in the lucrative weight management sector through a significant $2 billion acquisition of Versanis Bio. This strategic move centers on Bimagrumab, a

UnitedHealth Group experienced a significant market setback as its shares plummeted 4.6% amid mounting concerns over its planned acquisition of Amedisys. The downturn stems from the Federal Trade

Johnson & Johnson's financial stability faces new scrutiny as S&P Global Ratings places the healthcare giant's newly issued senior unsecured bonds under negative watch, despite maintaining their

Gilead Sciences experienced a notable uptick in its NASDAQ trading performance, with shares climbing 1.5% to reach $105.60. This movement brings the stock close to its 52-week high of $106.68

Die Stryker Corporation zeigt sich zum Jahresanfang 2025 in robuster Verfassung. Der Medizintechnikkonzern konnte im abgeschlossenen Geschäftsjahr 2024 einen beachtlichen Umsatzanstieg von 10

Die Pharmasparte von Johnson & Johnson sorgte diese Woche für Aufsehen mit der Bekanntgabe des vorzeitigen Abbruchs ihrer Phase-3-Studie E.mbrace am 13. Februar 2025. Der Gesundheitskonzern, dessen

Die Eli Lilly and Company hat zum 14. Februar 2025 ihre vierteljährliche Dividende auf 1,50 USD erhöht, was einer deutlichen Steigerung gegenüber der November-Ausschüttung von 1,30 USD entspricht

Zoetis, the leading veterinary pharmaceutical company, demonstrated robust performance in the fourth quarter with revenue climbing 5 percent to $2.3 billion. The adjusted earnings per share reached

Gilead Sciences is experiencing remarkable momentum on the NASDAQ, with its stock currently trading at $105.25, approaching its 52-week peak of $105.37. The biotechnology company has demonstrated

Boston Scientific Corporation's stock continues to demonstrate remarkable momentum, trading close to its 52-week peak of $107.17 and boasting an impressive year-to-date performance exceeding 62%

AbbVie has significantly strengthened its oncology portfolio through a groundbreaking collaboration with Xilio Therapeutics, marking a major expansion into cancer immunotherapy development. The